The world’s biggest medtech expects great things from its new surgical robot, but its best shot at leading a market with a new product remains renal denervation.
The pivotal trial of Medtronic’s hypertension device came out more than a year ago, yet the company has still not sought approval.
Abbott’s latest aortic valve launch is unlikely to gain it a meaningful slice of the market; meanwhile, Edwards’ attention has switched to tricuspid.
But does it hit hard enough?
Pivotal data on its closed-loop insulin delivery system look good, but Medtronic remains a threat.
A lot of money is sloshing around, and medical device start-ups are reaping the benefits.
Medtronic’s quarterly results yesterday might presage a recovery, and some groups are in dire need of one.